InsiderClue
Stocks · Health care · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC.

TENX Clue Score46
United States Fiscal year ends December CIK 0000034956
$1.87 +0.54% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.87 +6.86% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue0.0Operating income−52.7Net income−43.9Fiscal year 2017Operating income−9.2Net income−8.8Fiscal year 2018Operating income−6.9Net income−14.1Fiscal year 2019Operating income−8.6Net income−8.4Fiscal year 2020Operating income9.9Net income−9.9Fiscal year 2021Operating income−32.7Net income−32.5Fiscal year 2022Operating income11.1Net income11.0Fiscal year 2023Operating income−8.2Net income−7.7 −169.8%EPS, diluted−31.04Fiscal year 2024Revenue0.0Operating income−19.5Net income−17.6EPS, diluted−1.15Fiscal year 2025Revenue0.0Operating income−56.4Net income−52.6EPS, diluted−1.34
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 0.0 n/a n/a n/a n/a n/a n/a n/a 0.0 0.0
Growth
Operating income −52.7 −9.2 −6.9 −8.6 9.9 −32.7 11.1 −8.2 −19.5 −56.4
Net income −43.9 −8.8 −14.1 −8.4 −9.9 −32.5 11.0 −7.7 −17.6 −52.6
Growth −169.8%
EPS, diluted n/a n/a n/a n/a n/a n/a n/a −31.04 −1.15 −1.34

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−15.9Capital expenditure−0.0Free cash flow−15.9Fiscal year 2017Operating cash flow−12.1Capital expenditure−0.0Free cash flow−12.1Fiscal year 2018Operating cash flow−5.5Capital expenditure−0.0Free cash flow−5.5Fiscal year 2019Operating cash flow−7.6Capital expenditure−0.0Free cash flow−7.6Fiscal year 2020Operating cash flow−9.3Capital expenditure−0.0Free cash flow−9.3Fiscal year 2021Operating cash flow−10.9Capital expenditure−0.0Free cash flow−10.9Fiscal year 2022Operating cash flow−11.4Capital expenditure−0.0Free cash flow−11.4Fiscal year 2023Operating cash flow−5.9Fiscal year 2024Operating cash flow−14.8Fiscal year 2025Operating cash flow−35.8
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −15.9 −12.1 −5.5 −7.6 −9.3 −10.9 −11.4 −5.9 −14.8 −35.8
Capital expenditure −0.0 −0.0 −0.0 −0.0 −0.0 −0.0 −0.0 n/a n/a n/a
Free cash flow −15.9 −12.1 −5.5 −7.6 −9.3 −10.9 −11.4 n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash10.0Shareholders’ equity17.1Fiscal year 2017Cash1.6Shareholders’ equity8.9Fiscal year 2018Cash12.4Shareholders’ equity11.8Fiscal year 2019Cash4.9Shareholders’ equity3.8Fiscal year 2020Cash6.3Shareholders’ equity4.6Fiscal year 2021Cash5.6Shareholders’ equity4.2Fiscal year 2022Cash2.1Shareholders’ equity1.5Fiscal year 2023Cash9.8Shareholders’ equity8.1Fiscal year 2024Cash94.9Shareholders’ equity92.0Fiscal year 2025Cash97.6Shareholders’ equity97.1
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 10.0 1.6 12.4 4.9 6.3 5.6 2.1 9.8 94.9 97.6
Shareholders’ equity 17.1 8.9 11.8 3.8 4.6 4.2 1.5 8.1 92.0 97.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
0.0 n/a n/a n/a n/a n/a n/a n/a 0.0 0.0
Growth
0.0 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Growth
13.1 3.5 1.2 3.5 4.6 25.1 5.4 3.2 12.7 32.7
6.2 5.7 5.7 5.1 5.3 7.6 5.7 5.0 6.8 23.7
−52.7 −9.2 −6.9 −8.6 9.9 −32.7 11.1 −8.2 −19.5 −56.4
Growth −431.7% −174.5%
−8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−43.9 −8.8 −14.1 −8.4 −9.9 −32.5 11.0 −7.7 −17.6 −52.6
Growth −169.8%
Per share
n/a n/a n/a n/a n/a n/a n/a −31.04 −1.15 −1.34
n/a n/a n/a n/a n/a n/a n/a −31.04 −1.15 −1.34
Growth
n/a n/a n/a n/a n/a n/a n/a 0.2 15.3 39.2
n/a n/a n/a n/a n/a n/a n/a 0.2 15.3 39.2
Growth +6,046.9% +156.8%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 9 of 10 years on file.